August 15, 2019 / 8:28 PM / 2 months ago

BRIEF-FDA Approves Genentech’S Rozlytrek For People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer And NTRK Gene Fusion-Positive Solid Tumors

Aug 15 (Reuters) - Roche Holding AG:

* FDA APPROVES GENENTECH’S ROZLYTREK (ENTRECTINIB) FOR PEOPLE WITH ROS1-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER AND NTRK GENE FUSION-POSITIVE SOLID TUMORS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below